Project Grant R21CA307944
Award Date 4/1/26
Completion Date 3/31/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical evaluation of radiation-guided antibody-drug conjugates (ADCs) targeting Tax-Interacting Protein 1 (TIP1) as a novel therapeutic approach for non-small cell lung cancer (NSCLC). The research leverages a breakthrough...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $355,706 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025, through May 31, 2030. The award funds fundamental research aimed at understanding the role of RAMS11 (RNA Associated with Metastasis 11), a long noncoding RNA (lncRNA), in non-small cell lung cancer (NSCLC) development and progression. The research addresses a critical knowledge gap in cancer biology...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), through its Cancer Research Manpower program (CFDA 93.398), awarded The Washington University a Project Grant of $333,504 effective July 1, 2025, through July 31, 2027. This award funds research investigating the dynamics and function of peritoneal myeloid cells during colorectal cancer (CRC) peritoneal dissemination and the implications for immunotherapy. The research aims to elucidate the unique roles of myeloid...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University $101,771 under the Cancer Research Manpower program (CFDA 93.398) for a project grant beginning July 1, 2025, and concluding June 30, 2027. This award supports research investigating the impact of clonal hematopoiesis (CH)—specifically TET2 (Ten-Eleven Translocation 2) mutations in blood-forming cells—on solid tumor development and therapeutic response. The project will deliver fundamental...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- The National Cancer Institute awarded The Washington University a $3.18M Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 24, 2025, through August 31, 2029. The grant supports fundamental and translational research investigating the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research encompasses three primary objectives: elucidating the effector mechanisms by which NK cells constrain ICT efficacy; evaluating...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $680,598 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, with a completion date of August 31, 2030. The award supports fundamental research focused on decoding the Cullin-5 (CUL5) E3 ubiquitin ligase complex to engineer therapeutic T cells with enhanced durability and sustained effector function. The project...